You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

 

Online download statistics by month:

Online download statistics by month: March 2022 to August 2025

AbstractFullPdf
Mar 2022724763290
Apr 2022614634127
May 202230331689
Jun 202225226369
Jul 202220521559
Aug 202227828692
Sep 202225125673
Oct 202222123675
Nov 202221922474
Dec 202214614747
Jan 202315315566
Feb 202315816172
Mar 202317017395
Apr 202313113342
May 202319720376
Jun 202313914453
Jul 202312913061
Aug 202311912649
Sep 202322823052
Oct 202311111264
Nov 202315915976
Dec 2023848536
Jan 2024787859
Feb 2024999933
Mar 202415916168
Apr 202413013160
May 202411911962
Jun 202410811258
Jul 2024949456
Aug 2024757245
Sep 20247374224
Oct 2024878843
Nov 2024798034
Dec 202410210542
Jan 202511411745
Feb 202516516748
Mar 202510911058
Apr 202511111247
May 202511111360
Jun 2025585943
Jul 2025110
Aug 2025110
Total686470442822